GlobeNewswire Inc.··NaReviva Pharma Raises $10M via Public Offering to Fund Schizophrenia Drug Trial
Reviva Pharmaceuticals prices $10M offering at $1.50/share to fund brilaroxazine Phase 3 schizophrenia trial and operations.
RVPHwarrantspublic offering